Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
14 lessons
8mSS-31 and MOTS-c dominate mitochondrial peptide search. This list ranks the PeptIQ guides that answer dosage, timing, and stack questions without the forum noise.
9mSearch keeps landing on the same dosing pages. This listicle points you to the guides people actually use for MOTS-c, KLOW, SS-31, GHK-Cu, IGF-1 LR3, and retatrutide.
8mKLOW is a top PeptIQ page and a top search query. This guide ranks blend options, explains GLOW, and points to the deep dosing pages for each component.
8mRetatrutide owns PeptIQ's top blog slots. This listicle orders the beginner path: mix the vial, understand dosing, switch carefully, troubleshoot stalls, then consider stacks.
10mMost BPC-157 dose threads treat forum tables as fact. This guide separates published animal and limited human data from observational ranges people log, without turning either into a protocol.
9mThe newest peptide research batch is less about hype and more about the questions each compound answers. Retatrutide, tesamorelin, BPC-157, GHK-Cu, and MOTS-C all point at different tracking priorities.
12mRetatrutide dominates H1 logging, the Wolverine stack is real, and quick-log onboarding predicts who actually tracks. Our first semi-annual data report from thousands of real peptide logs.
9mSports medicine keeps pulling peptides into the conversation because recovery pressure is real. The hard part is separating promising biology from weak evidence, gray-market hype, and antidoping risk.
GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.
7mThe biggest peptide trend in 2026 may not be a molecule. It may be oversight, sourcing quality, and the ability to separate evidence from marketing.
7mEfsubaglutide alfa is a long-acting GLP-1 receptor agonist with new human trial data in drug-naive type 2 diabetes. Here is what the SUPER1 results actually show.
7mEDS changes the safety conversation around peptides. GHK-Cu, BPC-157, and TB-500 are discussed for tissue support, but EDS plus cardiac history should stay clinician-led.
7mWomen have unique considerations with peptides, from hormones and cycle changes to muscle retention, recovery, skin health, and tracking.
8mConfused about peptide compounding categories? This guide breaks down 503a compounding pharmacies, 503b outsourcing facilities, and why “research use only” is not a consumer pathway PeptIQ endorses.
Also available at /blog for legacy links.